HPV vaccine with routine HPV screening for ages 22–26
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman living in Sweden and between 22 and 26 years old
- You have not chosen to opt out of the national cervical/HPV screening program
- You agree to participate in the study and consent
- You are not currently pregnant
- You have not had your uterus removed (no total hysterectomy)
- You do not have a history of severe allergic reaction to the HPV vaccine or its ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving the HPV vaccine along with HPV screening to quickly reduce HPV infection and cervical cancer. It is for women aged 23-29 in Rwanda who choose to join.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This trial tests a new 15-valent HPV vaccine to see if it is safe and creates a strong immune response. If you are between 9 and 45 years old and have not had an HPV vaccine before, you may be able to join.
This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
Hear when a new HPV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.